Plakophilin-2 Promotes Tumor Development by Enhancing Ligand-Dependent and -Independent Epidermal Growth Factor Receptor Dimerization and Activation

REFERENCES

• Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411:355–365. http://dx.doi.org/10.1038/35077225.
   PubMed Web of Science ®Google Scholar
• Bogdan S, Klambt C. 2001. Epidermal growth factor receptor signaling. Curr. Biol. 11:R292–R295. http://dx.doi.org/10.1016/S0960-9822(01)00167-1.
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5:341–354. http://dx.doi.org/10.1038/nrc1609.
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. 2009. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21:177–184. http://dx.doi.org/10.1016/j.ceb.2008.12.010.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Pines G. 2012. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12:553–563. http://dx.doi.org/10.1038/nrc3309.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134. http://dx.doi.org/10.1016/j.cell.2010.06.011.
   PubMed Web of Science ®Google Scholar
• Batzer AG, Rotin D, Urena JM, Skolnik EY, Schlessinger J. 1994. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol. Cell. Biol. 14:5192–5201.
   PubMed Web of Science ®Google Scholar
• Hsu JM, Chen CT, Chou CK, Kuo HP, Li LY, Lin CY, Lee HJ, Wang YN, Liu M, Liao HW, Shi B, Lai CC, Bedford MT, Tsai CH, Hung MC. 2011. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat. Cell Biol. 13:174–181. http://dx.doi.org/10.1038/ncb2158.
   PubMed Web of Science ®Google Scholar
• Morishige M, Hashimoto S, Ogawa E, Toda Y, Kotani H, Hirose M, Wei S, Hashimoto A, Yamada A, Yano H, Mazaki Y, Kodama H, Nio Y, Manabe T, Wada H, Kobayashi H, Sabe H. 2008. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat. Cell Biol. 10:85–92. http://dx.doi.org/10.1038/ncb1672.
   PubMed Web of Science ®Google Scholar
• Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG, Schlessinger J, Pawson T. 1992. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360:689–692. http://dx.doi.org/10.1038/360689a0.
   PubMed Web of Science ®Google Scholar
• Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. 2010. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 464:783–787. http://dx.doi.org/10.1038/nature08827.
   PubMed Web of Science ®Google Scholar
• Bass-Zubek AE, Godsel LM, Delmar M, Green KJ. 2009. Plakophilins: multifunctional scaffolds for adhesion and signaling. Curr. Opin. Cell Biol. 21:708–716. http://dx.doi.org/10.1016/j.ceb.2009.07.002.
   PubMed Web of Science ®Google Scholar
• Chen X, Bonne S, Hatzfeld M, van Roy F, Green KJ. 2002. Protein binding and functional characterization of plakophilin 2. Evidence for its diverse roles in desmosomes and beta-catenin signaling. J. Biol. Chem. 277:10512–10522. http://dx.doi.org/10.1074/jbc.M108765200.
   PubMed Web of Science ®Google Scholar
• Mertens C, Kuhn C, Moll R, Schwetlick I, Franke WW. 1999. Desmosomal plakophilin 2 as a differentiation marker in normal and malignant tissues. Differentiation 64:277–290. http://dx.doi.org/10.1046/j.1432-0436.1999.6450277.x.
   PubMed Web of Science ®Google Scholar
• Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, Lerman BB, Markowitz SM, Ellinor PT, MacRae CA, Peters S, Grossmann KS, Drenckhahn J, Michely B, Sasse-Klaassen S, Birchmeier W, Dietz R, Breithardt G, Schulze-Bahr E, Thierfelder L. 2004. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat. Genet. 36:1162–1164. http://dx.doi.org/10.1038/ng1461.
   PubMed Web of Science ®Google Scholar
• Grossmann KS, Grund C, Huelsken J, Behrend M, Erdmann B, Franke WW, Birchmeier W. 2004. Requirement of plakophilin 2 for heart morphogenesis and cardiac junction formation. J. Cell Biol. 167:149–160. http://dx.doi.org/10.1083/jcb.200402096.
   PubMed Web of Science ®Google Scholar
• MacRae CA, Birchmeier W, Thierfelder L. 2006. Arrhythmogenic right ventricular cardiomyopathy: moving toward mechanism. J. Clin. Invest. 116:1825–1828. http://dx.doi.org/10.1172/JCI29174.
   PubMedGoogle Scholar
• Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang TH. 2008. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res. 68:1786–1796. http://dx.doi.org/10.1158/0008-5472.CAN-07-5547.
   PubMed Web of Science ®Google Scholar
• Papagerakis S, Shabana AH, Depondt J, Gehanno P, Forest N. 2003. Immunohistochemical localization of plakophilins (PKP1, PKP2, PKP3, and p0071) in primary oropharyngeal tumors: correlation with clinical parameters. Hum. Pathol. 34:565–572. http://dx.doi.org/10.1016/S0046-8177(03)00174-6.
   PubMed Web of Science ®Google Scholar
• Schwarz J, Ayim A, Schmidt A, Jager S, Koch S, Baumann R, Dunne AA, Moll R. 2006. Differential expression of desmosomal plakophilins in various types of carcinomas: correlation with cell type and differentiation. Hum. Pathol. 37:613–622. http://dx.doi.org/10.1016/j.humpath.2006.01.013.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Nakatsuji H, Takahashi M, Avirmed S, Fukawa T, Takemura M, Fukumori T, Kanayama H. 2012. Up-regulation of plakophilin-2 and down-regulation of plakophilin-3 are correlated with invasiveness in bladder cancer. Urology 79:240.e1–240.e8. http://dx.doi.org/10.1016/j.urology.2011.08.049.
   Google Scholar
• Wang LM, Kuo A, Alimandi M, Veri MC, Lee CC, Kapoor V, Ellmore N, Chen XH, Pierce JH. 1998. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc. Natl. Acad. Sci. U. S. A. 95:6809–6814. http://dx.doi.org/10.1073/pnas.95.12.6809.
   PubMed Web of Science ®Google Scholar
• Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. 2001. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer 94:774–782. http://dx.doi.org/10.1002/ijc.1557.
   PubMed Web of Science ®Google Scholar
• Hirsch DS, Shen Y, Wu WJ. 2006. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res. 66:3523–3530. http://dx.doi.org/10.1158/0008-5472.CAN-05-1547.
   PubMedGoogle Scholar
• Nickerson NK, Mohammad KS, Gilmore JL, Crismore E, Bruzzaniti A, Guise TA, Foley J. 2012. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One 7:e30255. http://dx.doi.org/10.1371/journal.pone.0030255.
   PubMed Web of Science ®Google Scholar
• Arteaga CL. 2011. ERBB receptors in cancer: signaling from the inside. Breast Cancer Res. 13:304. http://dx.doi.org/10.1186/bcr2829.
   PubMedGoogle Scholar
• Bill A, Schmitz A, Albertoni B, Song JN, Heukamp LC, Walrafen D, Thorwirth F, Verveer PJ, Zimmer S, Meffert L, Schreiber A, Chatterjee S, Thomas RK, Ullrich RT, Lang T, Famulok M. 2010. Cytohesins are cytoplasmic ErbB receptor activators. Cell 143:201–211. http://dx.doi.org/10.1016/j.cell.2010.09.011.
   PubMed Web of Science ®Google Scholar
• Su T, Bryant DM, Luton F, Verges M, Ulrich SM, Hansen KC, Datta A, Eastburn DJ, Burlingame AL, Shokat KM, Mostov KE. 2010. A kinase cascade leading to Rab11-FIP5 controls transcytosis of the polymeric immunoglobulin receptor. Nat. Cell Biol. 12:1143–1153. http://dx.doi.org/10.1038/ncb2118.
   PubMed Web of Science ®Google Scholar
• Chidgey M, Dawson C. 2007. Desmosomes: a role in cancer? Br. J. Cancer 96:1783–1787. http://dx.doi.org/10.1038/sj.bjc.6603808.
   PubMed Web of Science ®Google Scholar
• Desai BV, Harmon RM, Green KJ. 2009. Desmosomes at a glance. J. Cell Sci. 122:4401–4407. http://dx.doi.org/10.1242/jcs.037457.
   PubMed Web of Science ®Google Scholar
• Dusek RL, Attardi LD. 2011. Desmosomes: new perpetrators in tumour suppression. Nat. Rev. Cancer 11:317–323. http://dx.doi.org/10.1038/nrc3051.
   PubMed Web of Science ®Google Scholar
• Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK, Mikolka P, Pospisilova T, Spoustova T, Weis M, Paznekas WA, Wolf JH, Gutkind JS, Wilcox WR, Kozubik A, Jabs EW, Bryja V, Salazar L, Vesela I, Balek L. 2012. Receptor tyrosine kinases activate canonical WNT/beta-catenin signaling via MAP kinase/LRP6 pathway and direct beta-catenin phosphorylation. PLoS One 7:e35826. http://dx.doi.org/10.1371/journal.pone.0035826.
   PubMed Web of Science ®Google Scholar
• Lee CH, Hung HW, Hung PH, Shieh YS. 2010. Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Mol. Cancer 9:64. http://dx.doi.org/10.1186/1476-4598-9-64.
   PubMedGoogle Scholar
• Heibeck TH, Ding SJ, Opresko LK, Zhao R, Schepmoes AA, Yang F, Tolmachev AV, Monroe ME, Camp DGII, Smith RD, Wiley HS, Qian WJ. 2009. An extensive survey of tyrosine phosphorylation revealing new sites in human mammary epithelial cells. J. Proteome Res. 8:3852–3861. http://dx.doi.org/10.1021/pr900044c.
   PubMed Web of Science ®Google Scholar
• Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. 2012. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16:15–31. http://dx.doi.org/10.1517/14728222.2011.648617.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Chang SS, Hsu JL, Hung MC. 1 April 2013. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene http://dx.doi.org/10.1038/onc.2013.74.
   Google Scholar
• Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M. 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14:518–527. http://dx.doi.org/10.1038/nm1764.
   PubMed Web of Science ®Google Scholar
• Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S. 2010. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 5:e10312. http://dx.doi.org/10.1371/journal.pone.0010312.
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. 2006. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24:778–789. http://dx.doi.org/10.1200/JCO.2005.03.2375.
   PubMed Web of Science ®Google Scholar
• He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. 2005. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. U. S. A. 102:19075–19080. http://dx.doi.org/10.1073/pnas.0509603102.
   PubMed Web of Science ®Google Scholar
• Wells JA, McClendon CL. 2007. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450:1001–1009. http://dx.doi.org/10.1038/nature06526.
   PubMed Web of Science ®Google Scholar